Literature DB >> 310678

A controlled study of ANA+ RF- arthritis.

J E Linn, J G Hardin, J T Halla.   

Abstract

Thirty (7.5%) of 401 adult rheumatoid arthritis (RA) patients were antinuclear antibody positive (ANA+) and rheumatoid factor negative (RF-), and 15 of 16 patients who were followed for a year or longer remained so. Clinical, other laboratory, and radiographic parameters were compared among this group and 90 matched RA controls divided into ANA+RF+, ANA-RF+, and ANA-RF- groups. All groups were identical, except the ANA-RF- group, which had significantly fewer nodules and less destructive disease than the other three.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 310678     DOI: 10.1002/art.1780210606

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  8 in total

1.  Does sulphasalazine cause drug induced systemic lupus erythematosus? No effect evident in a prospective randomised trial of 200 rheumatoid patients treated with sulphasalazine or auranofin over five years.

Authors:  M M Gordon; D R Porter; H A Capell
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

2.  Seventh European Rheumatology Research Workshop. Glasgow, Scotland, March 6-7, 1987. Abstracts.

Authors: 
Journal:  Clin Rheumatol       Date:  1987-03       Impact factor: 2.980

3.  Seronegative polyarthritis.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-09-05

4.  A comparison of patients with seropositive and seronegative rheumatoid arthritis.

Authors:  J Edelman; A S Russell
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

5.  Seronegative chronic polyarthritis: clinical and serological correlates.

Authors:  J L Rasker; P Davis; P A Bacon
Journal:  Ann Rheum Dis       Date:  1980-12       Impact factor: 19.103

6.  The coexistence of rheumatoid arthritis and systemic lupus erythematosus.

Authors:  C Venegoni; M Chevallard; G Mele; G Banfi; M Carrabba
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

7.  Combination therapy for rheumatoid arthritis and drug-induced systemic lupus erythematosus.

Authors:  A A Borg; M J Davis; P T Dawes; M F Shadforth
Journal:  Clin Rheumatol       Date:  1994-09       Impact factor: 2.980

8.  Intraarticular expression of biologically active interleukin 1-receptor-antagonist protein by ex vivo gene transfer.

Authors:  G Bandara; G M Mueller; J Galea-Lauri; M H Tindal; H I Georgescu; M K Suchanek; G L Hung; J C Glorioso; P D Robbins; C H Evans
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.